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EDITORIAL

Twice neglected? Neglected diseases in neglected populations

It is unfortunately true that clinicians lack the necessary
evidence to know how to use medications properly in large
sections of the population and do not have optimal treatments to use for many neglected tropical diseases (NTDs).
NTDs

often

disproportionately

affect

and diseases caused by malnutrition, intoxications due to poorly regulated industrial activity (e.g., lead, mercury, and pesticides exposures)
and many other conditions (see Table 1) which disproportionately
affect the poor and disenfranchised, and about which too little is
known, or done.

neglected

Over recent decades, evidence-based medicine has been

populations that are left out of research efforts, such as

accepted as the standard upon which to base high quality treatment

children and pregnant women. As reliable access to safe,

guidelines. Contrasted with this is the problematic reality: We lack the

effective preventives and treatments can break the cycle
of poverty, illness, and ensuing debility that further perpet-

necessary evidence to know how to use medications properly in large
sections of the population, and we do not have optimal drugs to use
in many NTDs. Moreover, these conditions often disproportionately

uates poverty, it is of paramount importance to investigate

affect neglected populations such as children and pregnant women.3

and develop new medicines for neglected populations suf-

For example, two thirds of malaria deaths occur in children under

fering from NTDs. Furthermore, there is not only a need to

5 years of age, and at least 12 million pregnant women in sub-Saharan

develop and evaluate novel therapies, but also to ensure

Africa are exposed to malaria infection during pregnancy, resulting in

that these are affordable, available, and adapted to the
communities who need them. The NIH has proposed a “4
C's” framework which is relevant for neglected diseases

822 000 low birth weight deliveries related to maternal anaemia and
placental sequestration of the Plasmodium parasite.4 As reliable access
to safe, effective preventives and treatments can break the cycle of
poverty, illness, and ensuing debility that further perpetuates poverty,

and populations and should be leveraged for the study of

it is of paramount importance to investigate and develop new medi-

the Twice Neglected: Consider inclusion; Collect data from

cines for neglected populations suffering from NTDs. Furthermore,

neglected populations with neglected conditions; Charac-

there is not only a need to develop and evaluate novel therapies, but

terize differences through meaningful analysis; Communi-

also to ensure that these are affordable, available, and adapted to the

cate findings pertaining to neglected diseases and

communities who need them.

populations. With this editorial, the British Journal of Clinical Pharmacology hereby launches a call for high-quality
articles focusing on NTDs in special populations, to facili-
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NE G LE C T?

tate and encourage the reversal of this dual neglect.
The examples of harm from this double neglect are many. The geographical distance between high-income countries and populations
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with the highest burden of NTDs compounds a misperception in the
global North that NTDs are infrequent and their complications and
long-term sequelae of little consequence; the response tends to

Over a billion people worldwide experience morbidity and mortality

become more robust when an NTD begins to threaten the global

from conditions for which there are few evidence-based treatments.

North. Possibly because many NTDs do not lead to high acute mortal-

Neglected tropical diseases (NTDs) impose a devastating human,

ity, but to chronic, debilitating disease, they are perceived as

social and economic burden on predominantly impoverished

unimportant. However, even if many NTDs are not acutely deadly,

populations, mainly in tropical and subtropical areas where the most

such as Chagas disease, cutaneous leishmaniasis, and soil-transmitted

vulnerable, marginalized populations of the world live.1,2 It is esti-

nematodes, they have large impacts on individual well-being and

mated that they are responsible for over 25 million disability-adjusted

capabilities, local economies, and health systems. Importantly, they

1

life years (DALYs) lost worldwide. The World Health Organization

directly impede human flourishing, as measured, for example, by the

(WHO) definition of NTDs includes the phrase “ancient diseases of

key metric the United Nations Human Development Index.5,6 On the

poverty,” which though poetic leaves out emerging infectious threats

other hand, some NTDs also have high mortality, particularly

Br J Clin Pharmacol. 2022;88:367–373.
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TABLE 1
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Selected neglected tropical diseases (NTDs)

WHO-defined NTDs: (REF)

Other neglected diseases include:

Buruli ulcer (Mycobacterium ulcerans)
Chagas disease
Dengue and Chikungunya
Dracunculiasis
Echinococcosis
Foodborne trematodiases
Human African trypanosomiasis
Leishmaniasis
Leprosy
Lymphatic filariasis
Mycetoma chromoblastomycosis and other deep
mycoses
Onchocerciasis
Rabies
Scabies and other ectoparasitoses
Schistosomiasis
Soil-transmitted helminthiases
Snakebite envenoming
Taeniasis and cysticercosis
Trachoma and yaws

Tuberculosis (including with the spectrum of rifampicin resistance)
Malaria (including with partial artemisinin resistance and/or artemisinin-combination
therapy
[ACT] partner drug resistance; including and non-falciparum Plasmodium species)
Melioidosis
Filoviruses/viral haemorrhagic fevers
Hantavirus
Zika virus
Loiasis
Toxocariasis and other larva migrans
Amebiasis
Babesiosis
Balantidiasis
Giardiasis
Bartonella
Bovine tuberculosis in humans
Cholera
Enteric Gram-negative pathogens
Leptospirosis
Relapsing fever
Bejel, Pinta
Q fever
Mycetoma and other deep mycoses
Paracoccidiomycosis
Arboviral infections
Enterovirus 71
HTLV-1, HTLV-2, non-HIV retroviruses
Rift Valley fever
Myiasis
Podoconiosis
Endemic fungi (cryptococcosis; histoplasmosis)
Henipaviruses
Group A streptococcus
Sickle cell anaemia

concentrated in neglected populations; for example, the mortality and

expanded the list to include 40 conditions unified in their ability to

morbidity burdens for malaria, TB meningitis, and disseminated TB are

perpetuate poverty and cause chronic debility.14 Control of these

centred in children, and Ebola is almost uniformly fatal both to

neglected diseases is variable—they range from almost eliminated

pregnant women and to their neonates, if left untreated.7 Visceral

(e.g., dracunculiasis) to precipitously expanding in both prevalence

leishmaniasis in many settings is concentrated in those younger than

and range (e.g., dengue).15 They have a singular commonality: their

8

15 years of age. A large portion of individuals worldwide who die

devastating impact on impoverished communities. However, the list

each year from diarrhoeal disease are children, particularly with

is not exhaustive! Other situations exist where a dearth of evidence

underlying malnutrition.9,10 It is well documented that there are often

results in uncertainty about clinical management, including drug-

altered physiological factors that can affect drug pharmacokinetics,

resistant pathogens such as tuberculosis and malaria and emerging

leading in many cases to related safety and efficacy concerns in

infectious diseases such as melioidosis, hantavirus, filoviruses, and

vulnerable populations, such as those with prevalent co-morbidities,

Zika virus.

pregnant women, and young children, particularly those with malnutrition.11,12

4
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WHAT IS A NEGLECTED POPULATION?

For our purposes, a “neglected population” is “a population in whom
there is insufficient evidence to inform the safe and effective use of
medication.” Clinical trials often stipulate stringent eligibility criteria

The WHO lists a diverse set of 20 diseases or disease groups as pri-

which are not reflective of the real-life clinical population who require

ority “neglected tropical diseases”; see Table 1.13 Others have

treatment. Many clinical and demographic factors impact on disease
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burden and drug disposition, and whilst it is increasingly recognized

5.2

|

Geospatial

that it is ethically imperative to study drugs in the populations in
whom they are to be used, this is rarely the case in practice.16 An

Geospatial inequity foments research neglect too; nations in the

increasing body of work argues for and exemplifies the study of drugs

global South are often left out of initiatives to improve health that dis-

in pregnant and lactating women and their infants, young children,

proportionately serve the global North. The current COVID-19 pan-

and adolescents,17,18 but even in these there remains an unacceptable

demic provides a searing example of why the approach to infectious

delay between the time of drug licensing and the availability of data

illness must be global and equitable. Out of the two billion doses of

to inform safe and effective use in such populations.19 Where inter-

SARS-CoV2 vaccine that had been administered worldwide by August

secting characteristics exist that render an individual “complex”—such

of 2021, only 1.4% of them were delivered in low-income countries.23

as young, malnourished children with malaria or obese or elderly indi-

Uneven and inadequate vaccine distribution to regions where

viduals with prevalent co-morbid conditions —clinicians are forced

COVID-19 cases are surging offers an excellent opportunity for the

to make a “best guess” as to the appropriate drug treatment for that

virus to multiply and mutate within innumerable human hosts, with

individual, perhaps leading to segments of the population that are

obvious downstream effects for all countries irrespective of their level

thrice neglected (the next vanguard, once the twice neglected receive

of resources. Furthermore, tropical diseases are anticipated to become

their fair due in research).

global problems, with climate change.24 With a warming planet, den-

20

gue has become widespread, and leishmaniasis is now endemic in Italy
and Chagas in the Southern United States.25 An inversion or epidemi-
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ological shift is occurring: As diseases of affluence come to the cities
of the global South, neglected diseases of poverty may come to the
global North. Clearly, decolonizing globally minded research attitudes

Who is doing the neglecting? The neglect in this case extends across

is needed in the face of these new waves.

multiple domains, from the research enterprise (pharmaceutical manufacturers, funding bodies, academic researchers, regulatory bodies,
and scientific literature publishing enterprise) to governments, and

5.3

|

Regulatory

across the public and private sectors. There are four agents of neglect
that we shall consider here: financial, geospatial, regulatory, and pro-

Even once funding hurdles are cleared, investigators with the best

tectionist. These synergize with each other and create overlapping

intentions to do rigorous research on neglected conditions in

conditions that foster more neglect.

neglected populations are often thwarted by regulatory barriers. Both
global and country-specific research ethics committees and regulatory
bodies can be hesitant about performing research on populations who

5.1

|

Financial

are perceived to be vulnerable (and thus, in turn, rendered even more
vulnerable by being left out of research by these roadblocks). Further-

Many neglected diseases and conditions occur in under-resourced,

more, regulatory barriers have frequently been construed, and per-

underserved, settings with inadequate access to medical research and

haps misconstrued, as non-negotiable and static absolutes rather than

care, perpetuating their neglect. The financing of research on these

as principles that dynamically parallel evolving ethical stances.

topics has often been relegated to non-governmental, non-corporate
entities, and public–private partnerships that are often external to the
affected area, with a focus on a single disease; this approach is limited

5.4

|

Protectionist

as it does not contend with the reality that there are often multiple
overlapping medical and socioeconomic conditions at play in a given

A lack of financial investment in research on the safety and efficacy

region that intersect differently in different populations.15 In effec-

of drugs in special populations has at times been nominally justified

tively leveraging the Global Fund for AIDS, tuberculosis, and malaria,

by a desire to protect the “vulnerable” from harm. This has only

there exists a tension between the benefits of focusing on specific

compounded the research neglect of key populations suffering

diseases and the reality that special populations affected by these dis-

undue burdens of NTDs. Too long has a misplaced belief in

eases are also affected by other overlapping poverty-related diseases.

protecting so-called vulnerable populations “protected them to

Drug donations from pharmaceutical manufacturers have been a key

death” by creating a knowledge void around their treatment and

element in Mass Drug Administration campaigns to address filariasis,

care.26 In essence, imagining these populations to be special and in

21

helminthic infection, and other parasitic diseases,

but donations

need of protection has engendered their neglect in research. Lastly,

from Industry of other kinds (e.g., research support and infrastruc-

the choicelessness of individuals affected by NTDs in under-

ture)22 could amplify this positive impact from the private sector so

resourced areas serves as perhaps the starkest counterpoint and

that NTDs can be studied in special populations, including incorpora-

rebuttal to the animus-fuelled assertion that these conditions are

tion of pharmacovigilance systems and assessment of overall societal

inevitable, acceptable, and unworthy of study because they arise

impacts.

from personal or behavioural failings.
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experimentation. However, the latter describes the reality of how
many drugs for neglected tropical diseases have been developed for
special populations.

With non-neglected conditions, sample size and inclusion criteria usu-

The regulatory aspects of study of drugs in special populations

ally mean that data on highly refined subgroups of patients emerges

are complex. In some settings, strong regulatory advice that drug man-

from the research (i.e., the different considerations for initiating a cal-

ufacturers study drugs in special populations such as children or

cium channel blocker as opposed to an ACE inhibitor for hyperten-

orphan conditions such as extensively drug resistant tuberculosis

sion). However, for neglected conditions, a further neglect emerges—

(XDR-TB) has been incentivized with certain benefits, such as

the neglect of patient complexity. The study of problems that dispro-

vouchers and patent extensions. There has been some criticism of this,

portionately affect the poor can be needlessly homogenizing—

particularly as it has not led to improvement in price or availability for

ignoring individual patient characteristics which better funded condi-

many drugs that were given such incentives (e.g., miltefosine,

tions incorporate in their evidence-based solutions.

benznidazole, and several other drugs for NTDs remain difficult to

Another aspect of neglect hinges on the assumption of commensu-

obtain, prohibitively expensive or both, after the pharmaceutical com-

rability of one population for another (i.e., the idea that it is possible to

panies that registered them in North America obtained hundreds of

extrapolate efficacy, safety, and pharmacokinetic data from one popu-

millions of dollars in benefits).31 Some have argued that the situation

lation, for example, healthy European males in their 50s to another, for

of inequitable study of special populations calls for a “carrot and stick

example, pregnant African women in their twenties). This assumption

approach,” where not just incentives, but strict enforcement mecha-

does not hold true in many situations, particularly where there are dif-

nisms with punitive measures attached are needed. The passage of

ferences in physiology altering pharmacokinetic or pharmacodynamic

the Pediatric Research Equity Act (PREA) and the Best Pharmaceuti-

parameters, pharmacogenetics, or intercurrent disease states (e.g., renal

cals for Children Act (BPCA), introduced as part of the FDA Safety and

clearance differences in pregnancy or early childhood). In cases where

Innovation Act (FDASIA), took this approach.32,33 It was accompanied

the research neglect relates to geopolitical or socioeconomic factors

by guidance on how to comply with the acts, which delineated the

(refugees, prisoners, nomadic groups, etc.), there may be an indirect

need for study in four main age groups of children: neonates, infants,

impact on pharmacokinetic parameters through intermediaries such as

children, and adolescents. The PREA (viewed as the “stick”) requires

adherence and instability of access to food or care, but overall, it may

that pharmaceutical companies submit a plan for a paediatric study

be reasonable to extrapolate pharmacokinetic parameters from one

with each new drug application. The drug can be launched in adults

population to another. Dietary factors may differ substantially across

even if not yet tested in children, but the sponsor must submit its

populations, so medicines tested in North America or Europe and then

assessments in children by a certain final due date. BPCA (viewed as

brought to Africa or Asia can encounter different dietary patterns

the “carrot”) grants sponsors who conduct paediatric studies of their

which may affect absorption and permeability of the medicine,

products 6 months of market exclusivity to the company for that pae-

depending on the compound. Similarly, pharmacogenetic differences

diatric product. Over 85 exclusivity determinations have been granted

may result in clinically significant differences in drug exposure.27

by the FDA since September of 2007. Similar “carrot and stick” initia-

Another consideration surrounds the question of when can we
extrapolate safety and efficacy of repurposed drugs from one condi-

tives do not yet exist for pregnant, obese, or elderly individuals even
though they carry disproportionately high burdens of some diseases.

tion to another poorly understood or neglected condition, and when
can we not? This can be done well in some conditions, as in the
repurposing of rifamycins for leprosy prevention and, less well, as in
the effort to take a “kitchen sink” approach to COVID-19 treatment

7 | H O W CA N N O V E L T R E A T M E N T S B E
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based only on limited preclinical data but no rational clinical pharmacologic basis. An example of this is seen with highly protein-bound

The clinical evaluation of a potential treatment in these “complex” or

drugs' EC50 against SARS-COV2 that cannot be clinically achieved in

“neglected groups” requires first a balancing of risks and benefits,

humans using safe doses.28 A more rational stepwise model-informed

including whether or not there is better data for alternative treatments

drug repurposing approach has been proposed, integrating prepara-

in the vulnerable subpopulation. An example of harm caused by a

tory, reactive, and retrospective action in response to new patho-

skewed balancing of these risks was treating malaria in pregnant

gens.29,30 In essence, situations of desperation call for more high-

women and young children with chloroquine long past the point of

quality rational science, and not less.

widespread chloroquine resistance, because it was perceived as safe

There is strong potential for meta-analyses of pooled individual

for the vulnerable, even though these groups were also at the highest

patient data (IPD) to speed up the answering of key questions, pro-

risk of the potentially severe consequences of failed malaria treatment.

vided they adjust for relevant heterogeneity (e.g., disease severity,

It also requires innovative approaches, including partnership

dose, and other drivers of drug exposure). Overall, there is an ethical

between clinical pharmacologists and pharmacometricians. Physiologi-

imperative not to shift risk from well-controlled, carefully monitored

cally based pharmacokinetic modelling uses a “bottom-up” approach

small studies to widespread uninformed use in the general population

based on knowledge of cellular processes to predict drug exposure

which may be considered to amount to (often poorly controlled)

within a specific population. Models can be adapted to encompass
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characteristics such as nutritional status, hepatic or renal dysfunction,

neglected diseases, occurring in the most neglected populations

pregnancy, concurrent administration of interacting medications, and

(i.e., the “Twice-neglected”).

other factors which may render a population “neglected.”

34–36

This

Many have driven a call for sex to be considered an experimental

can provide a starting point for clinical trials to confirm the predicted

variable in research, supported by the British Journal of Pharmacology's

dosing strategies in vulnerable and neglected patient groups. Optimal

themed issue on this important subject.41,42 The NIH Policy on sex as

design theory uses mathematical approaches to predict the ideal sam-

an experimental variable includes an easy-to-remember four Cs

pling schedule for the most efficient study design. This enables the

framework that is as relevant for neglected diseases and populations:

minimum number of participants to be included with the least invasive

Consider: when designing studies, either take the neglected population

sampling schedule in order to yield the highest quality informa-

and/or disease into account or explain why you have not; Collect: tab-

tion.37,38 Population pharmacokinetic modelling explores sources of

ulate data from neglected populations that take into account differ-

variability between individuals and adds to the understanding of how

ences from the general population; Characterize: analyse data in such

different “neglected” characteristics may impact on drug exposure and

a way that differences by population can be detected; Communicate:

thereby on the appropriate dosing schedules to ensure safe, effective

report and publish data about neglected diseases and neglected

treatment.39 Combinations of these techniques have the potential to

populations.43

yield high quality, efficient clinical studies and advance prompt under-

Through the “Twice Neglected” series, the British Journal of Clini-

standing of sources of variability in drug exposure and thus potentially

cal Pharmacology will encourage the conduct and facilitate the dissem-

efficacy and safety, particularly in these difficult-to-study groups.40

ination of high-quality articles that will reduce the neglect of diseases
of poverty in complex populations. Progress requires multi-disciplinary
collaboration, knowledge-transfer, and a visionary, ethics-rooted

8 | H O W C A N N E W D R U G S F O R NT D s BE
DEVELOPED?

approach.
In times past, some major drug discoveries occurred almost fortuitously (e.g., Alexander Fleming's discovery of penicillin) but solutions

The Drugs for Neglected Diseases Initiative (DNDi, available at:

to

https://dndi.org/wp-content/uploads/2021/03/DNDi-StrategicPlan-

populations, will not be discovered without the deliberate, targeted

NTDs,

especially

when

impacting

neglected

vulnerable

2021-2028.pdf) was created in response to the frustration of clini-

focus of the research community, involving strong partnerships

cians and the desperation of patients faced with medicines that were

between community, industry, academia, and clinicians, with multi-

ineffective, unsafe, unavailable, unaffordable, or that had never been

disciplinary collaboration between cutting-edge technologies and a

developed at all. DNDi embraces the power of innovation, open sci-

vision which prioritizes alleviation of human suffering. Clinical

ence, partnerships, and advocacy to find solutions to a great injustice:

pharmacology is in its essence cross-disciplinary and brings together

the lack of medicines for life-threatening diseases that disproportion-

many of the key skills and actors required to transform such a vision

ately impact poor and marginalized people. Through harnessing scien-

into a reality with disruptive, silo-colliding thinking and efforts.

tific advances in drug discovery, technologies to improve the

Neglect results from persistent inattention, and as a community of

efficiency and accelerate the pace of the R&D process, including artifi-

clinical pharmacologists, we hereby launch this call for papers to draw

cial intelligence (AI)-driven drug discovery tools, novel imaging, diag-

awareness to these conditions and special populations throughout

nostic, and clinical trial design and operations technologies, and AI-

the processes of drug discovery and evaluation, to facilitate knowl-

driven data analysis are being employed. Evaluation of a range of

edge transfer, to stimulate dialogue and interaction, and ultimately to

strategies and compounds, including fast-evolving techniques such as

be part of the solution to this global problem. May it be received as a

the use of host-targeted therapies or development of specific mono-

clarion call to arms.

clonal antibodies alongside repurposing of older agents, aims to
increase the therapeutic repertoire available for evaluation in clinical
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